The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Silibinin has demonstrated anti-cancer activity in the laboratory for several different
cancer types, including prostate cancer. Silibinin was originally obtained from milk thistle.
Silybin-Phytosome, an oral form of silibinin, has been tested previously in prostate cancer
patients to determine the safety of high-dose treatment. This study is for men with prostate
cancer who are planning to have their prostate surgically removed. Participants will be given
Silybin-Phytosome three times a day from enrollment in the study until the time of their
surgery. Participation in this study will not affect the timing of surgery. We obtain blood
and urine samples at the start and completion of the trial in addition to prostate tissue
from the surgery. These samples will be analyzed for the effect of Silybin-Phytosome at the
end of the study.